Fotemustine, Teniposide and Dexamethasone in Treating Patients with CNS Lymphoma

Wu, Jing-Jing; Wang, Xin-Hua; Li, Ling; Li, Xin; Zhang, Lei; Sun, Zhen-Chang; Fu, Xiao-Rui; Ma, Wang; Chang, Yu; Zhang, Xu-Dong; Han, Li-Juan; Zhang, Ming-Zhi

추천

검색

자료유형: 학술저널

저자정보: Wu, Jing-Jing (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Wang, Xin-Hua (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Li, Ling (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Li, Xin (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Zhang, Lei (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Sun, Zhen-Chang (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Fu, Xiao-Rui (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Ma, Wang (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Chang, Yu (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Zhang, Xu-Dong (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Han, Li-Juan (Institute of Clinical Medicine,The First Affiliated Hospital of Zhengzhou University) Zhang, Ming-Zhi (Institute of Clinical Medicine,The First Af)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제11호

발행연도: 2014.1

수록면: 4,733 - 4,738 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: We developed and evaluated a regimen including fotemustine, teniposide and dexamethasone (FTD) for treating patients with central nervous system (CNS) lymphoma based on pharmacokinetic properties of individual agents and in combination. Patients and Methods: In a comparison study, 8 patients with primary CNS lymphoma (PCNSL) and 8 with secondary CNS lymphoma (SCNSL) were treated with FTD (comprising fotemustine 100 mg/m2, 1h infusion, day 1; teniposide 60 mg/m2, >0.5 h infusion, on day 2, 3, 4; dexamethasone 40 mg, 1h infusion, on day 1, 2, 3, 4 and 5; and methotrexate 12 mg, cytosine arabinoside 50 mg plus dexamethasone 5 mg intrathecally, on day 2 and 7). Cycles were repeated every 3 weeks. After response assessment, patients received whole brain radiotherapy. Results: Of the 8 PCNSL patients, 4 (50%) achieved CR and 3 (38%) PR, an overall response rate of 88%. Four patients (50%) were in continuing remission at the end of this study after a median follow-up of 30 months (range 10 to 56 months). Of the 8 SCNSL patients the overall response rate was 63% (CR+PR: 38%+25%). All responses were achievable with predictable toxicity mainly reflecting reversible myelosuppression. Conclusion: This study suggests that FTD could be an effective treatment for CNS lymphoma, and is worthy of further evaluation.

#Central nervous system #lymphoma #chemotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요